Viking Therapeutics DEF 14A: Executive Compensation Details
Ticker: VKTX · Form: DEF 14A · Filed: Apr 8, 2025 · CIK: 1607678
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: VKTX
TL;DR
Viking Therapeutics dropped its DEF 14A, showing exec comp & equity awards for 2021-2024. Check it out!
AI Summary
Viking Therapeutics, Inc. filed a DEF 14A on April 8, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2021, 2022, 2023, and 2024. The filing includes information on the change in fair value of outstanding equity awards granted in prior years and awards granted in the covered years for both principal executive officers (PEO) and non-principal executive officers (Non-PEO).
Why It Matters
This filing provides transparency into how Viking Therapeutics compensates its top executives and the value of equity awards, which can influence investor perception and executive decision-making.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present new material risks to the company.
Key Numbers
- 2021-2024 — Fiscal Years Covered (Executive compensation and equity award data is provided for these years.)
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Filer of the DEF 14A
- 0000950170-25-052162 (filing_id) — Accession Number for the filing
- 20250408 (date) — Filing Date
- 20250520 (date) — Period of Report
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing is a definitive proxy statement used to solicit shareholder votes and provide detailed information on matters such as executive compensation, director elections, and other corporate governance issues.
What specific types of compensation are detailed in this filing for Viking Therapeutics?
The filing details executive compensation, including changes in the fair value of equity awards granted in prior and covered years, for both principal executive officers (PEO) and non-principal executive officers (Non-PEO).
For which fiscal years does Viking Therapeutics provide compensation data?
Viking Therapeutics provides compensation data for the fiscal years ending December 31, 2021, 2022, 2023, and 2024.
What is the filing date of this DEF 14A for Viking Therapeutics?
This DEF 14A filing for Viking Therapeutics was filed on April 8, 2025.
Where is Viking Therapeutics, Inc. headquartered?
Viking Therapeutics, Inc. is headquartered at 9920 Pacific Heights Blvd, Suite 350, San Diego, CA 92121.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 8, 2025 regarding Viking Therapeutics, Inc. (VKTX).